Ocular side effects of novel anti-cancer biological therapies

Abstract To examine the ocular side effects of selected biological anti-cancer therapies and the ocular and systemic prognosis of patients receiving them. We retrospectively reviewed all medical records of patients who received biological anti-cancer treatment from 1/2012 to 12/2017 and who were tre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vicktoria Vishnevskia-Dai, Lihi Rozner, Raanan Berger, Ziv Jaron, Sivan Elyashiv, Gal Markel, Ofira Zloto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/01f14d4204674dacb1141f282afa57e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01f14d4204674dacb1141f282afa57e1
record_format	dspace
spelling	oai:doaj.org-article:01f14d4204674dacb1141f282afa57e12021-12-02T14:12:07ZOcular side effects of novel anti-cancer biological therapies10.1038/s41598-020-80898-72045-2322https://doaj.org/article/01f14d4204674dacb1141f282afa57e12021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80898-7https://doaj.org/toc/2045-2322Abstract To examine the ocular side effects of selected biological anti-cancer therapies and the ocular and systemic prognosis of patients receiving them. We retrospectively reviewed all medical records of patients who received biological anti-cancer treatment from 1/2012 to 12/2017 and who were treated at our ocular oncology service. The following data was retrieved: primary malignancy, metastasis, type of biological therapy, ocular side effects, ophthalmic treatment, non-ocular side effects, and ocular and systemic disease prognoses. Twenty-two patients received biological therapies and reported ocular side effects. Eighteen patients (81.8%) had bilateral ocular side effects, including uveitis (40.9%), dry eye (22.7%), and central serous retinopathy (22.7%). One patient (4.5%) had central retinal artery occlusion (CRAO), and one patient (4.5%) had branch retinal vein occlusion (BRVO). At the end of follow-up, 6 patients (27.27%) had resolution of the ocular disease, 13 patients (59.09%) had stable ocular disease, and 3 patients (13.64%) had progression of the ocular disease. Visual acuity improved significantly at the end of follow-up compared to initial values. Eighteen patients (81.8%) were alive at study closure. Biological therapies can cause a wide range of ocular side effects ranging from dry eye symptoms to severe pathologies that may cause ocular morbidity and vision loss, such as uveitis, CRAO and BRVO. All patients receiving biological treatments should be screened by ophthalmologists before treatment, re-screened every 4–6 months during treatment, and again at the end of treatment. Patients on biological treatment who have ocular complaints should be urgently referred to ocular consultation for early identification and early intervention.Vicktoria Vishnevskia-DaiLihi RoznerRaanan BergerZiv JaronSivan ElyashivGal MarkelOfira ZlotoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Vicktoria Vishnevskia-Dai Lihi Rozner Raanan Berger Ziv Jaron Sivan Elyashiv Gal Markel Ofira Zloto Ocular side effects of novel anti-cancer biological therapies
description	Abstract To examine the ocular side effects of selected biological anti-cancer therapies and the ocular and systemic prognosis of patients receiving them. We retrospectively reviewed all medical records of patients who received biological anti-cancer treatment from 1/2012 to 12/2017 and who were treated at our ocular oncology service. The following data was retrieved: primary malignancy, metastasis, type of biological therapy, ocular side effects, ophthalmic treatment, non-ocular side effects, and ocular and systemic disease prognoses. Twenty-two patients received biological therapies and reported ocular side effects. Eighteen patients (81.8%) had bilateral ocular side effects, including uveitis (40.9%), dry eye (22.7%), and central serous retinopathy (22.7%). One patient (4.5%) had central retinal artery occlusion (CRAO), and one patient (4.5%) had branch retinal vein occlusion (BRVO). At the end of follow-up, 6 patients (27.27%) had resolution of the ocular disease, 13 patients (59.09%) had stable ocular disease, and 3 patients (13.64%) had progression of the ocular disease. Visual acuity improved significantly at the end of follow-up compared to initial values. Eighteen patients (81.8%) were alive at study closure. Biological therapies can cause a wide range of ocular side effects ranging from dry eye symptoms to severe pathologies that may cause ocular morbidity and vision loss, such as uveitis, CRAO and BRVO. All patients receiving biological treatments should be screened by ophthalmologists before treatment, re-screened every 4–6 months during treatment, and again at the end of treatment. Patients on biological treatment who have ocular complaints should be urgently referred to ocular consultation for early identification and early intervention.
format	article
author	Vicktoria Vishnevskia-Dai Lihi Rozner Raanan Berger Ziv Jaron Sivan Elyashiv Gal Markel Ofira Zloto
author_facet	Vicktoria Vishnevskia-Dai Lihi Rozner Raanan Berger Ziv Jaron Sivan Elyashiv Gal Markel Ofira Zloto
author_sort	Vicktoria Vishnevskia-Dai
title	Ocular side effects of novel anti-cancer biological therapies
title_short	Ocular side effects of novel anti-cancer biological therapies
title_full	Ocular side effects of novel anti-cancer biological therapies
title_fullStr	Ocular side effects of novel anti-cancer biological therapies
title_full_unstemmed	Ocular side effects of novel anti-cancer biological therapies
title_sort	ocular side effects of novel anti-cancer biological therapies
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/01f14d4204674dacb1141f282afa57e1
work_keys_str_mv	AT vicktoriavishnevskiadai ocularsideeffectsofnovelanticancerbiologicaltherapies AT lihirozner ocularsideeffectsofnovelanticancerbiologicaltherapies AT raananberger ocularsideeffectsofnovelanticancerbiologicaltherapies AT zivjaron ocularsideeffectsofnovelanticancerbiologicaltherapies AT sivanelyashiv ocularsideeffectsofnovelanticancerbiologicaltherapies AT galmarkel ocularsideeffectsofnovelanticancerbiologicaltherapies AT ofirazloto ocularsideeffectsofnovelanticancerbiologicaltherapies
_version_	1718391824628842496

Ocular side effects of novel anti-cancer biological therapies

Ejemplares similares